Researchers are looking for people with myasthenia gravis (MG) to participate in a multinational phase 2A clinical trial to evaluate the safety, tolerability and effectiveness of the investigational drug UCB7665.
UCB7665, under development by UCB Pharma, is administered via subcutaneous (under-the-skin) injection and is designed to reduce the severity of muscle weakness and fatigue in individuals with MG, as indicated via the Quantitative Myasthenia Gravis (QMG) and Myasthenia Gravis – Activities of Daily Living profile (MG-ADL) scores.
Trial length is approximately 18 weeks, during which participants will visit with study investigators approximately 20 times.
In order to be eligible to participate, individuals must:
- be at least 18 years old
- have a diagnosis of MG
- meet additional criteria
The trial is taking place at more than a dozen study sites across the United States, and support for travel costs may be available.